Skip to ContentSkip to Navigation
About us Latest news News News articles

Synthesis and evaluation of dopaminergic prodrugs designed for transdermal iontophoretic drug delivery. Highly water-soluble amino acid ester prodrugs applicable for the treatment of Parkinson’s disease

21 May 2012

PhD ceremony: Mr. J. de Graan, 14.30 uur, Academiegebouw, Broerstraat 5, Groningen

Dissertation: Synthesis and evaluation of dopaminergic prodrugs designed for transdermal iontophoretic drug delivery. Highly water-soluble amino acid ester prodrugs applicable for the treatment of Parkinson’s disease

Promotor(s): prof. B.H.C. Westerink

Faculty: Mathematics and Natural Sciences

Dopamine agonists are used as pharmacotherapy for patients with Parkinson's disease. In his thesis Jeroen de Graan describes the preparation and evaluation of highly water-soluble derivatives of the dopamine agonist 5-OH-DPAT. These derivatives are chemically coupled compounds of 5-OH-DPAT with other molecules, i.e. amino acids. In pharmacy these compounds are named prodrugs. A prodrug is a non-pharmacologically active compound which will release the active drug after conversion in the body.

De Graan's research has led to several findings. First, highly water-soluble prodrugs were synthesized which showed sufficient stability while in solution in the iontophoretic patch (sufficient sustainability), but released the drug on entry in the bloodstream. Second, by coupling 5-OH-DPAT to dipeptides (two combined amino acids) he obtained even more stable prodrugs. Third, 5-OH-DPAT could be administered in a controlled manner, which would facilitate the development of a feedback system. Finally, he found that the iontophoretic delivery of a highly water-soluble prodrug of 5-OH-DPAT led to a prolongation of the pharmacological effect in comparison to 5-OH-DPAT itself.

These results show that the application of prodrugs can be advantageous for the administration of dopamine agonists and other drugs by transdermal iontophoresis. Further research of this pharmaceutical dosage form could eventually lead to a new pharmacotherapy of patients with Parkinson's disease.

Last modified:13 March 2020 01.02 a.m.
Share this Facebook LinkedIn
View this page in: Nederlands

More news

  • 03 April 2025

    IMChip and MimeCure in top 10 of the national Academic Startup Competition

    Prof. Tamalika Banerjee’s startup IMChip and Prof. Erik Frijlink and Dr. Luke van der Koog’s startup MimeCure have made it into the top 10 of the national Academic Startup Competition.

  • 01 April 2025

    NSC’s electoral reform plan may have unwanted consequences

    The new voting system, proposed by minister Uitermark, could jeopardize the fundamental principle of proportional representation, says Davide Grossi, Professor of Collective Decision Making and Computation at the University of Groningen

  • 01 April 2025

    'Diversity leads to better science'

    In addition to her biological research on ageing, Hannah Dugdale also studies disparities relating to diversity in science. Thanks to the latter, she is one of the two 2024 laureates of the Athena Award, an NWO prize for successful and inspiring...